Report: China Life invests US $42.4m in Series B round for Yingke Biopharmaceutic

Yingke was established in 2022 and is engaged in the R&D of pharmaceutical drugs

Share

Report china life invests us 4m in series b round for yingke biopharmaceutic
Picture of Editorial team

Editorial team

THIS PREMIUM INSIGHT IS FOR SUBSCRIBERS ONLY.

Stay ahead with precise, independent journalism of APAC's insurance markets.

Unlocked access today:

Already subscribed? Log in here

Read next

new-engineering-risks-underscore-importance-of-tailor-made-coverage
funding-question-slows-repurchase-of-parametric-cat-cover
ReinBrief-2024-09-24
bancassurance-to-benefit-from-economic-growth-in-asean
insurers-poised-to-capture-asias-us60bn-data-centre-opportunity
chinas-motor-insurers-need-to-ramp-up-risk-management-amid-rise-of-self-driving-cars-china-taiping
asia-pac-reinsurers-post-strong-set-of-first-ifrs-17-results
investing-in-ai-boundaries-key-to-incorporating-genai-across-insurance-value-chain
small-and-medium-chinese-p-and-c-insurers-face-profitability-challenge
monte-carlo-reflections-flatter-rates-shifts-focus-to-long-term-stability

Share this article